Consumers Advised to Verify Compounded GLP-1 Medications as Formulations Are Not FDA-Approved

A report highlights that while active ingredients like semaglutide and tirzepatide in compounded GLP-1 medications are found in FDA-approved products, the compounded formulations themselves have not undergone FDA review for safety, effectiveness, or manufacturing quality. Consumers are urged to confirm the regulatory status of such medications, as results from clinical trials on FDA-approved versions may not apply to compounded alternatives.